KIT and mastocytosis: Although more studies are necessary to evaluate the clinical potential of these inhibitors, our data show promise targeting SPHKs as an effective therapy, perhaps in combination with existing therapies, in the treatment of aggressive mastocytosis and other diseases involving D816V-KIT mutations.